Bharat Serums and Vaccines Limited

Other

Zydus Bsv Pharma Private Limited

Sangeeta Hanurmesh Rivankar

Gautam Vinod Daftary

Srikanth Annappa Pai

Vasanthan Mani

Suresh Kumar Natarajan

Cyril Fernandez Lourdnathan Joseph

Shilpa Sudhakar Kocharekar

Girish Narasimha Shanbhag

Praveen Kumar Subbappa

Cyril Fernandez Joseph

A safety housing based implant/medicament injecting system. The system includes a needle assembly prefilled with an implant/medicament for injection and an injecting needle/cannula, a housing for accommodating the needle assembly under usual bias inside said housing, a plunger means having a plunger rod configured for stage-wise forward motion including an initial-injecting plunger forward motion with the needle assembly within the housing to first engage the needle assembly with the housing and a subsequent continuing-injecting plunger forward motion independent of the needle assembly for injecting the implant/medicament. The needle assembly configured to return post-injecting to be secured inside said housing blocking any subsequent use thereof.

Safety housing based implant/medicament injecting system

A safety housing based implant/medicament injecting system. System includes a needle assembly prefilled implant/medicament for injection and an injecting needle/cannula, a housing for accommodating the needle assembly under usual bias inside said housing, a plunger means having a plunger rod configured for stage wise forward motion including an initial injecting plunger forward motion with the needle assembly within the housing to first engage the needle assembly with the housing and subsequent continuing injecting plunger forward motion independent of the needle assembly for injecting of the implant/medicament, and post injecting return of the needle assembly secured inside said housing blocking any subsequent use thereof.

Safety housing based implant/ medicament injecting system

The present invention provides a long circulating non-pegylated liposomal doxorubicin hydrochloride composition for parenteral administration and a process for its preparation. The circulation time in Swiss albino mice is at least 25 times longer than conventional non-liposomal formulations. The non-pegylated liposomes are stable, exhibit low toxicity and have been found to be efficacious in different tumor models.

Non-pegylated long-circulating liposomes

The invention discloses a stable intravenous Propofol oil-in-water emulsion composition having mixed preservatives of low toxicity that is capable of withstanding accidental contamination of bacteria and fungi. The preservative system employed comprising of monoglyceryl ester of lauric acid (Monolaurin) and a member selected from (a) capric acid and/or its soluble alkaline salts or its monoglyceryl ester (Monocaprin); (b) edetate; and (c) capric acid and/or its soluble alkaline salts or its monoglyceryl ester (Monocaprin) and edetate.

Intravenous propofol emulsion compositions having preservative efficacy

The present invention provides aqueous Ifosfamide compositions and a process for their preparation, in which the compositions have a reduced toxicity over and above the concomitant use of the uroprotective agent, Mesna. Aqueous Ifosfamide compositions can be prepared at concentrations as high has 1,1000 mg/ml.

Aqueous ifosfamide compositions for parenteral administration and a process for their preparations

Sterile pharmaceutical stable autoclaved clear aqueous compositions of propofol (2,6-Diisopropyl phenol) suitable for parenteral administration are described. The compositions essentially consist of a complex of propofol with 2-hydroxypropyl-&#x3b2;-cyclodextrin in a weight ratio of 1:30&#x2013;1:60. This complex of propofol with 2-hydroxypropyl-&#x3b2;-cyclodextrin produces a clear aqueous composition that is stable to autoclaving. The composition is effective as an anaesthetic agent. The process of making these synergistic compositions has been described.

Clear aqueous composition comprising propofol and hydroxypropyl-beta-cyclodextrin

Parenteral compositions of oil-coated-Amphotericin B in structured-emulsion form, having LD50 of at least 400 mg/kg in mice and process for making the same have been described. The process essentially requires dispersing Amphotericin B in oily vehicle and dispersing emulsifier in the aqueous phase. The process of present invention is simple, cost effective and gives a stable product suitable for parenteral administration. Amphotericin B emulsion compositions prepared by the process of the present invention may be administered to human beings and animals for the treatment of fungal infections, with substantially equivalent or greater efficacy and low drug toxicity as compared to the conventional composition containing Amphotericin B and sodium desoxycholate.

Growing community of inventors

Thane, India

Sangeeta Hanurmesh Rivankar